Taipei Exchange (TPEx) Provides a Supportive Ecosystem for Innovation and Sustainable Growth
8.6.2022 11:00:00 EEST | Business Wire | Press release
The Taipei Exchange (TPEx), has successfully built an efficient multi-tiered fund-raising platform to foster the growth of innovative companies within the Taiwan capital market while also focusing on Environmental, Social and Governance (ESG) practices.
Support for Innovation
Along with a Mainboard of well-established companies, TPEx provides an Emerging Stock market, which includes Emerging Stock board and Pioneer Stock board, for companies prior to IPO, and the Go Incubation Board for Startup and Acceleration Firms. This multi-tiered structure aims to support the growth of enterprises through various stages of their development.
In line with Taiwan government policies, TPEx has been devoted to fostering innovative industries, high-tech industries, and small and medium-sized enterprises (SMEs), thus driving the momentum of Taiwan’s economy. Since its establishment 28 years ago, TPEx has assisted more than 2,300 public companies to gain access and contribute to the Taiwan capital market.
Environmental, Social and Governance (ESG) Practices
While providing a convenient mechanism for fundraising, TPEx also assists listed companies in setting their sustainable operations and ESG practices in response to the impact of climate change and international attention to the sustainability issue. As The European Union’s (EU’s) proposed new directive on corporate sustainability reporting (CSRD) is planned to come into effect in January 2023, TPEx has long been engaged in enhancing ESG information transparency, including requiring listed companies to prepare Sustainability reports in accordance with GRI Standards and strengthening the disclosure of Sustainability Reporting with reference to international norms under TCFD and SASB.
TPEx has also made efforts to publish relevant information and guidelines to assist listed companies in strengthening ESG-related disclosure. The rate of listed companies that prepared sustainability reports for 2020 was around 20% and according to the "CG WATCH 2020 Report” from the Asian Corporate Governance Association (ACGA), Taiwan’s concerted effort over the past two years to enhance its CG ecosystem has moved it from fifth to fourth position.
In order to deepen sustainable growth, TPEx has strengthened the function of the board of directors for listed companies and continues to expand the scope of TPEx-listed companies that are required to prepare Sustainability reports. Companies are encouraged to enhance communications with stakeholders, and from June 2023, TPEx-listed companies will also be required to appoint a Chief Governance Officer.
To meet the needs for ESG investing and sustainable financing globally, TPEx has been promoting diversified ESG investment products and responsible investment. TPEx has launched several sustainability-themed indexes to steer market funds toward investments that address climate change and environmental sustainability. The Chairman of TPEx, Philip Chen, stated that, “TPEx commits to upholding ESG values to strengthen our core businesses. TPEx will continue to promote capital raising functionality, innovative and sustainable related products, information transparency, and efficient fair-trading mechanisms; building a vibrant and innovative world-class capital market.”
For more information about the Taipei Exchange, please visit: https://www.tpex.org.tw/web/index.php?l=en-us
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608005017/en/
Contact information
Winnie Tsai: wanling@tpex.org.tw
Iris Yang: irisyang@tpex.org.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom